Literature DB >> 9507456

Bioavailability of amoxycillin in pigs.

H Agersø1, C Friis.   

Abstract

Amoxycillin was administered to pigs intravenously (i.v.), intramuscularly (i.m.) and orally (p.o.), in a cross-over design to examine the bioavailability (F) of various drug formulations. These included: a sodium salt for reconstitution in water and administration i.v.; trihydrate salt in an oil base for intramuscular administration producing 'conventional' duration of plasma concentrations; a trihydrate salt in oil base giving prolonged (LA) duration, and a trihydrate powder for oral administration in solution. The concentration of amoxycillin in plasma was measured by high-performance liquid chromatography, and its pharmacokinetic variables were assessed for the individual pigs by use of noncompartmental methods. Following i.v. administration (8.6 mg/kg), amoxycillin was eliminated rapidly with a mean residence time (MRT) of 1.4 h. After i.m. administration of the conventional formulation (14.7 mg/kg), the plasma amoxycillin concentration peaked at 2 h at 5.1 micrograms/mL. The bioavailability was 0.83. Intramuscular administration (14.1 mg/kg) of the long acting formulation (i.m. LA), lead to two peaks in plasma at 1.3 and 6.6 h. The bioavailability was calculated to be 1.11. After p.o. administration to fasted pigs, peak concentration was reached after 1.9 h, and the bioavailability was 0.33. In fed pigs, the corresponding values were 3.6 h and 0.28. Data showed that treatment of respiratory tract diseases in pigs by p.o. dosing alone, may not be optimal, because of the relatively low bioavailability and the fact that infections often result in reduced feed and water consumption. A rational treatment regime for susceptible respiratory pathogens includes an initial i.m. injection, followed by p.o. dosing every 12 h. Alternatively, the long acting formulation may be administered i.m. in a dose of 15 mg/kg, which would lead to active plasma concentrations for approximately 48 h.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507456     DOI: 10.1046/j.1365-2885.1998.00107.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  7 in total

1.  Comparative pharmacokinetics and bioavailability of amoxycillin in chickens after intravenous, intramuscular and oral administrations.

Authors:  K Abo El-Sooud; Y H Al-Tarazi; M M Al-Bataineh
Journal:  Vet Res Commun       Date:  2004-10       Impact factor: 2.459

2.  Pharmacokinetics of amoxicillin trihydrate in Desert sheep and Nubian goats.

Authors:  H A Elsheikh; A A Taha; A E Khalafalla; I A Osman; I A Wasfi
Journal:  Vet Res Commun       Date:  1999-12       Impact factor: 2.459

3.  Effect Oral Administration Ampicillin on the Ecological Balance of rat Enterococcal gut Microbiota.

Authors:  Taha Ahmed Benabbou; Halima Zadi Karam; Nour-Eddine Karam
Journal:  Curr Microbiol       Date:  2019-01-28       Impact factor: 2.188

4.  Impact of three ampicillin dosage regimens on selection of ampicillin resistance in Enterobacteriaceae and excretion of blaTEM genes in swine feces.

Authors:  D Bibbal; V Dupouy; J P Ferré; P L Toutain; O Fayet; M F Prère; A Bousquet-Mélou
Journal:  Appl Environ Microbiol       Date:  2007-06-08       Impact factor: 4.792

5.  LC-MS/MS measurement of ampicillin residue in swine tissues at 5 days after in-feed administration.

Authors:  Kouko Hamamoto; Yasuharu Mizuno
Journal:  J Vet Med Sci       Date:  2015-06-18       Impact factor: 1.267

6.  The effects of amoxicillin treatment of newborn piglets on the prevalence of hernias and abscesses, growth and ampicillin resistance of intestinal coliform bacteria in weaned pigs.

Authors:  Jinhyeon Yun; Satu Olkkola; Marja-Liisa Hänninen; Claudio Oliviero; Mari Heinonen
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

7.  Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs.

Authors:  Chongshan Dai; Tingting Zhao; Xing Yang; Xilong Xiao; Tony Velkov; Shusheng Tang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.